- $504.78m
- -$62.82m
- $262.60m
Brief: Arvinas Announces Positive Phase 1 Data For Arv-102 Showing Greater Than 50% Lrrk2 Degradation In The Csf Of Patients With Parkinson’S Disease Treated For 28 Days
Arvinas up after early-stage trial shows drug lowers key Parkinson's marker
Arvinas Q4 revenue misses; names Randy Teel as CEO
Brief: Arvinas Announces Appointment Of Randy Teel, Ph.D., As President, Chief Executive Officer, And Director
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Biotech firm Arvinas' Q3 net loss narrows
Brief: Arvinas Q3 Revenue USD 41.9 Million
U.S. RESEARCH ROUNDUP- BlackRock, Goldman Sachs, Netflix
U.S. RESEARCH ROUNDUP-Factset, Metlife, Replimune Group
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party
Brief: Arvinas Expects $4.5 Million Costs For Workforce Reduction - SEC Filing
Brief: Arvinas Provides Update On Collaboration With Pfizer
Brief: Logos Global Management Reports 8.6% Stake In Arvinas
Brief: Arvinas Announces FDA Acceptance Of The New Drug Application
Arvinas Q2 revenue falls 71%, net loss widens
Arvinas Inc expected to post a loss of 100 cents a share - Earnings Preview
Brief: Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus
Arvinas falls after Leerink downgrades